Daniel Petrylak, MD of Yale School of Medicine discusses what’s next for patient with bladder cancer after checkpoint inhibition therapy at the 2017 Annual Meeting Annual Meeting in Chicago, IL.
If a urothelial carcinoma patient is progressing on checkpoint inhibitors, whatÂ’s next for the patient?
